Basic information
- Name:
Stavudine
- CAS No.:
3056-17-5
- Molecular Structure:
- Formula:
- C10H12N2O4
- Molecular Weight:
- 224.22
- Deleted CAS:
- 132425-31-1
- Synonyms:
- Thymidine,2',3'-didehydro-3'-deoxy-;Thymine,1-(2,3-dideoxy-b-D-glycero-pent-2-enofuranosyl)- (7CI,8CI);2'-Thymidinene, 3'-deoxy- (8CI);2',3'-Didehydro-3'-deoxythymidine;3'-Deoxy-2',3'-didehydrothymidine;Avostav;BMY 27857;D 4T (nucleoside);NSC163661;Stag;Stavir;Virostav;Zerit;d4T;
- Density:
- 1.374 g/cm3
- Melting Point:
- 159-160 °C
- Solubility:
- Water solubility: 5-10 g/100 mL at 21 °C
- Appearance:
- white powder
- Hazard Symbols:
Xi- Risk Codes:
- 36/37/38
- Safety Description:
- 26-S36 Details
Famous Chemical Enterprises
-
Livzon -
Total -
Shell -
Dupont -
Exxonmobil -
Akzonobel -
Basf -
Bayer -
BP
Please post your buying leads,so that our qualified suppliers will soon
contact you!
*Required Fields
Chemistry
IUPAC Name:1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
Molecular Formula:C10H12N2O4
Molecular Weight:224.213280：
Melting Point:159-160°C
refractive index:-46 ° (C=0.69, H2O)
storage temp.:20°C
Water Solubility:5-10 g/100 mL at 21°C
CAS DataBase Reference:3056-17-5(CAS DataBase Reference)
EPA Substance Registry System:3056-17-5(EPA Substance)
Synonyms of STAVUDINE(3056-17-5):
STAVUDINE;ZERIT;3'-deoxythymidin-2'-ene;3'-DEOXY-2',3'-DIDEHYDROTHYMIDINE;1-((2R,5S)-5-HYDROXYMETHYL-2,5-DIHYDRO-FURAN-2-YL)-5-METHYL-1H-PYRIMIDINE-2,4-DIONE;1-[2,3-DIDEOXY-BETA-D-GLYCERO-PENT-2-ENOFURANOSYL]THYMINE;2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE;2',3'-DIHYDRO-2',3'-DEOXYTHYMIDINE
Categories of STAVUDINE(3056-17-5):
Active Pharmaceutical Ingredients;chiral;Antivirals for Research and Experimental Use;Biochemistry;Chemical Reagents for Pharmacology Research;Nucleosides and their analogs;Nucleosides, Nucleotides & Related Reagents;Bases & Related Reagents;Nucleotides;Pharmaceuticals;API's
History
STAVUDINE(3056-17-5) was the fourth antiretroviral drug on the market, its patent expired in the United States on 2008-06-25.
STAVUDINE(3056-17-5) was first synthetized in the sixties by Jerome Horwitz,subsequently reconsidered as an anti-HIV agent by the Rega Institute for Medical Research in Belgium.
STAVUDINE(3056-17-5) was approved by the U.S.FDA in Jun 24, 1994 for adults and in Sep 6, 1996 for pediatric use.
STAVUDINE(3056-17-5) was approved by the U.S.FDA for once-a-day dosing in 2001.
Uses
Toxicity Data With Reference
| 1. | dni-hmn-lym 20 µmol/L | MOPMA3 Molecular Pharmacology. 39 (1991),625. | ||
| 2. | cyt-orl-mus 600 mg/kg/3D-C | EMMUEG Environmental and Molecular Mutagenesis. 18 (1991),168. | ||
| 3. | orl-rat LD50:4 g/kg | YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. 40 (1998),1944. | ||
| 4. | ivn-rat LD50:>1200 mg/kg | YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. 40 (1998),1944. | ||
| 5. | orl-mus LD50:1 g/kg | YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. 40 (1998),1944. | ||
| 6. | ivn-mus LD50:1 g/kg | YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. 40 (1998),1944. | ||
| 7. | orl-dog LD :>2 g/kg | YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. 40 (1998),1944. | ||
| 8. | ivn-dog LD :>1680 mg/kg | YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. 40 (1998),1944. |
Safety Profile
Safety Information of STAVUDINE(3056-17-5):
Hazard Codes:Xi 
Risk Statements:36/37/38
36/37/38:Irritating to eyes, respiratory system and skin
Safety Statements:26-36
26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice
36:Wear suitable protective clothing
WGK Germany:2
RTECS:XP2075000
Hazardous Substances Data:3056-17-5(Hazardous Substances Data)
Moderately toxic by ingestion and intravenous routes. Mutation data reported. When heated to decomposition it emits toxic vapors of NOx.